Skip to content

The dressing and securement of tunnelled, cuffed Central Venous Access Devices (CVADs), in acute care paediatrics: a pilot, randomised controlled trial.

Randomised controlled trial of tissue adhesive, combined securement and dressing product or external stabilisation devices versus standard care (bordered polyurethane) dressings to prevent central venous access device failure in paediatric acute care patients with tunnelled, cuffed central venous access devices: the CASCADE Junior trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12614000280606
Acronym
The CASCADE Junior Trial
Enrollment
48
Registered
2014-03-17
Start date
2014-06-02
Completion date
2016-05-02
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Children admitted to an acute care facility frequently require the insertion of a CVAD for the administration of medication and fluids. When treatment is required for an extended duration, clinicians often elect to insert a tunnelled, cuffed CVAD. These CVADs are associated with a high rate of failure, including CVAD-related bloodstream infection (BSI). In order to prevent failure, dressings, such as bordered polyurethane (BPU), are used to protect the CVAD insertion site from contamination. Additional securement devices, such as sutures, are used to reduce movement of the catheter. New products, including tissue adhesive (TA), sutureless securement devices (SSD), and combined securement and dressing products (CSD), are available to clinicians to provide securement and dressings for CVAD. It is not known whether these new products are effective at reducing CVAD failure, in comparison to standard care (BPU and suture). The primary aim of this research is to evaluate the feasibility of launching a full-scale efficacy trial, using pre-defined feasibility criteria for recruitment, retention and protocol fidelity. The secondary aim is to compare the effectiveness of dressings and securement products on CVAD failure due to infection, occlusion, dislodgement, thrombosis, or breakage, for children with tunnelled, cuffed CVAD in acute care.

Interventions

Patients in this study have central venous access devices (CVADs) used in medical, surgical, anaesthetic and intensive care departments, and only paediatric patients. Consenting parents or legal guardians, and patients (if appropriate) will have their tunnelled, cuffed CVADs secured with one of the following randomly assigned dressings and securements: Arm 1: Tissue Adhesive (TA) is a medical grade 'superglue' (cyanoacrylate) used mainly to close skin acerations/wounds as an alternative to su

Patients in this study have central venous access devices (CVADs) used in medical, surgical, anaesthetic and intensive care departments, and only paediatric patients. Consenting parents or legal guardians, and patients (if appropriate) will have their tunnelled, cuffed CVADs secured with one of the following randomly assigned dressings and securements: Arm 1: Tissue Adhesive (TA) is a medical grade 'superglue' (cyanoacrylate) used mainly to close skin acerations/wounds as an alternative to sutures and staples. A bordered polyurethane dressing will also be applied. Arm 2: Sutureless Stabilisation Device (SSD) have a large adhesive padded footplate with locking clasp made of hard plastic or velcro. SSD are used in addition to bordered polyurethane. Arm 3: Combined securement and dressing product: extra-reinforced borders, with an absorbent layer around the polyurethane claimed to ‘wick’ moisture away from the wound Arm 4 (Control): Bordered polyurethane (BPU) dressings involve a clear polyurethane with an added external adhesive border of foam or cloth fabric. They will also have their CVAD secured with prolene sutures. The randomly allocated dressing will be applied until completion of therapy, hospital discharge or at 4 weeks. The dressing will be applied at CVAD insertion and then changed every 7 days, or on disruption of the dressing integrity.

Sponsors

Griffith University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
0 to 18 Years
Healthy volunteers
No

Inclusion criteria

Inclusion criteria: *Patient requires the insertion of a tunnelled, cuffed CVAD for >24 hours; *Will remain in admitted to the RCH or Lady Cilento Childrens Hospital for >24 hours; and *Parent or legal guardian, and child if developmentally appropriate, gives informed consent.

Exclusion criteria

Exclusion criteria: *Non-tunnelled, peripherally inserted, dialysis, or implanted CVADs or pulmonary artery catheters; *Current bloodstream infection; *CVAD to be inserted through diseased, burned or scarred skin; *Allergy to study product; and *Previous study enrolment in this admission to hospital.

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 1, 2026